Evidence map›Paper›PMID 35742486›Full record

ArticleInternational journal of environmental research and public health2022

SARS-CoV-2 Risk Quantification Model and Validation Based on Large-Scale Dutch Test Events.

Bas Kolen, Laurens Znidarsic, Andreas Voss, Simon Donders, Iris Kamphorst, Maarten van Rijn, Dimitri Bonthuis, Merit Clocquet, Maarten Schram, Rutger Scharloo and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bas KolenDepartment Values, Technology and Innovation, Delft University of Technology, 2628 CD Delft, The Netherlands.
Laurens ZnidarsicDepartment Values, Technology and Innovation, Delft University of Technology, 2628 CD Delft, The Netherlands.
Andreas VossRadboudumc, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-0689-3773
Simon DondersBreda University of Applied Sciences, 4817 JS Breda, The Netherlands.
Iris KamphorstBreda University of Applied Sciences, 4817 JS Breda, The Netherlands.
Maarten van RijnBreda University of Applied Sciences, 4817 JS Breda, The Netherlands.
Dimitri BonthuisFieldlab Program Committee, 1507 CC Zaandam, The Netherlands.
Merit ClocquetFieldlab Program Committee, 1507 CC Zaandam, The Netherlands.
Maarten SchramFieldlab Program Committee, 1507 CC Zaandam, The Netherlands.
Rutger ScharlooFieldlab Program Committee, 1507 CC Zaandam, The Netherlands.
Tim BoersmaFieldlab Program Committee, 1507 CC Zaandam, The Netherlands.
Tim StobernackRadboudumc, 6525 GA Nijmegen, The Netherlands.
Pieter van GelderDepartment Values, Technology and Innovation, Delft University of Technology, 2628 CD Delft, The Netherlands.ORCID 0000-0002-0001-0351

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In response to the outbreak of SARS-CoV-2, many governments decided in 2020 to impose lockdowns on societies. Although the package of measures that constitute such lockdowns differs between countries, it is a general rule that contact between people, especially in large groups of people, is avoided or prohibited. The main reasoning behind these measures is to prevent healthcare systems from becoming overloaded. As of 2021 vaccines against SARS-CoV-2 are available, but these do not guarantee 100% risk reduction and it will take a while for the world to reach a sufficient immune status. This raises the question of whether and under which conditions events like theater shows, conferences, professional sports events, concerts, and festivals can be organized. The current paper presents a COVID-19 risk quantification method for (large-scale) events. This method can be applied to events to define an alternative package of measures replacing generic social distancing.

Indexed as

COVID-19SARS-CoV-2Communicable Disease ControlCOVID-19 VaccinesGovernmentHumansCOVID-19 VaccinesCOVID-19eventsinfection risk

Identifiers

PMID35742486
PMCPMC9223577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.